Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stable Black and White Kidney Transplant Recipients.

ABSTRACT: Interpatient variability in tacrolimus pharmacokinetics is due in part to variation in metabolism by cytochrome P-450 3A5 and 3A4 and membrane transport by P-glycoprotein. We evaluated the combined role CYP3A5*3 and CYP3A4*1B genotypes have on tacrolimus pharmacokinetics in 65 stable Black and White kidney transplant recipients receiving maintenance immunosuppression of tacrolimus and mycophenolic acid. Tacrolimus apparent clearance, trough (C_12h), C_12h/Dose, AUC_0-12, and AUC_0-12/Dose as well as CYP3A5 *3 (rs776746) variants responsible for loss of protein function and CYP3A4-1B (rs2740574) associated with increased CYP3A4 function were assessed. To investigate the association of tacrolimus pharmacokinetics with the CYP3A5 *3 and CYP3A4*1B genoty

SUBMITTER: Brazeau D 

PROVIDER: S-EPMC12516915 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature